NEW YORK CITY, NY / ACCESS Newswire / March 15, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...

To join the GSK class action, go to https://rosenlegal.com/submit-form/?case_id=34609 or call Phillip Kim, Esq. toll-free at ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Larson Financial Group LLC cut its holdings in GSK plc (NYSE:GSK – Free Report) by 52.7% during the fourth quarter, according ...

Biopharma deal activity climbed in early 2025, reaching $37.38 billion in the first two months, up from $35.66 billion a year ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

GSK plc (LON:GSK – Get Free Report)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,444 ($18.73) and traded as high ...

After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...